A clinical pharmacology, single topically dose study to evaluate the safety and pharmacokinetics of M605110 in patients with acne vulgaris

A clinical pharmacology, single topically dose study to evaluate the safety and pharmacokinetics of M605110 short contact therapy in patients with acne vulgaris

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031220537

Enrollment

Registered

2022-12-25

Start date

2023-02-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne vulgaris

Interventions

5%M605110 or M605110 placebo will be administered to affected area of patients singlely.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients with acne vulgaris who are 18 to 49 years of age at the time of informed consent

Exclusion criteria

Exclusion criteria: (1)Patients with a history or merger of cardiac, hepatic, plumonary, renal, hematologic, or other diseases considered inappropriate for paticipation in the clinical study (2)Patients with inflamed cysts/induration (3) Patients with diseases other than acne vulgaris at the planned application site of study drug (4)Patients who are judged to be clinically abnormal by the principal (sub) investigator based on clinical tests, vital signs, and electrocardiogram (5)Patients who are judged to be unsuitable as subject by the principal (sub) investigator

Design outcomes

Primary

Measure	Time frame
Safety, Pharmacokinetics	—

Contacts

Public Contact- Clinical Trials Information

Maruho Co.,Ltd. Kyoto R&D Center

ctinfo@mii.maruho.co.jp+81-75-325-3279

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026